{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-009981","form_type":"8-K","ticker":"HIND","cik":"0001427570","company_name":"Vyome Holdings, Inc","filed_at":"2023-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.827174+00:00","generated_at":"2026-06-14T23:29:48.815244+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ReShape Lifesciences Q1 2023 revenue down 6.3% to $2.3M; operating expenses cut 42.9% YoY","bullets":["Revenue $2.3M (down 6.3% YoY); gross margin improved to 53.5% from 49.9%.","Sales & marketing expenses fell 53.5% to $2.2M; R&D down 39.2% to $0.5M.","Cash $9.1M at March 31, 2023; no debt; expects runway into 2024.","Raised $12.7M in 2023 via February public offering ($10.2M) and April direct offering ($2.5M).","Lap-Band 2.0 PMA supplement submission to FDA expected in coming weeks; feedback by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-009981","json":"https://secwatch.observer/filing/0001558370-23-009981.json","markdown":"https://secwatch.observer/filing/0001558370-23-009981.md","text":"https://secwatch.observer/filing/0001558370-23-009981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427570/000155837023009981/0001558370-23-009981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427570/000155837023009981/rsls-20230515x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T23:29:48.815244+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"32d4d9913a9f7225a8ba520c83562fc0670542e2","claim":"Vyome Holdings, Inc reported for the three months ended March 31, 2023 results: revenue $2.3 million.","evidence_excerpt":"impact revenue for the remainder of 2023 and move ReShape closer to cash flow breakeven.” ​ First Quarter Ended March 31, 2023, Financial and Operating Results ​ Revenue totaled $2.3 million for the three months ended March 31, 2023, which represents a contraction of 6.3%, or $0.2 million compared to the same period in 2022. The primary reason for the decrease is a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000155837023009981/0001558370-23-009981-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the three months ended March 31, 2023"},{"label":"Revenue","value":"$2.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}